You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 7,060,827


✉ Email this page to a colleague

« Back to Dashboard


Title:Intermediates useful for making 2,4-pyrimidinediamine compounds
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s): Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (San Mateo, CA), Holland; Sacha J. (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Menlo Park, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (Burlingame, CA), Li; Hui (Millbrae, CA), Rossi; Alexander B. (San Francisco, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:Jun 01, 2004
Application Number:10/858,343
Claims:1. A 4-pyrimidineamine compound according to structural formula (II): ##STR00066## including salts, hydrates, solvates and N-oxides thereof, wherein: X is N; Y is selected from the group consisting of O, S, SO, SO.sub.2, SONR.sup.36, NH, NR.sup.35 and NR.sup.37; Z is selected from the group consisting of O, S, SO, SO.sub.2, SONR.sup.36, NH, NR.sup.35 and NR.sup.37; R.sup.5 is selected from the group consisting of R.sup.6, (C1 C6) alkyl optionally substituted with one or more of the same or different R.sup.8 groups, (C1 C4) alkanyl optionally substituted with one or more of the same or different R.sup.8 groups, (C2 C4) alkenyl optionally substituted with one or more of the same or different R.sup.8 groups and (C2 C4) alkynyl optionally substituted with one or more of the same or different R.sup.8 groups; R.sup.6 is selected from the group consisting of hydrogen, an electronegative group, --OR.sup.d, --SR.sup.d, (C1 C3) haloalkyloxy, (C1 C3) perhaloalkyloxy, --NR.sup.cR.sup.c, halogen, (C1 C3) haloalkyl, (C1 C3) perhaloalkyl, --CF.sub.3, --CH.sub.2CF.sub.3, --CF.sub.2CF.sub.3, --CN, --NC, --OCN, --SCN, --NO, --NO.sub.2, --N.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O)NR.sup.cR.sup.c; --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O)NR.sup.cR.sup.c, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --C(NH)NR.sup.cR.sup.c, --OC(O)R.sup.d, --SC(O)R.sup.d, --OC(O)OR.sup.d, --SC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --SC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c, --SC(NH)NR.sup.cR.sup.c, --[NHC(O)].sub.nR.sup.d, --[NHC(O)].sub.nOR.sup.d, --[NHC(O)].sub.nNR.sup.cR.sup.c and --[NHC(NH)].sub.nNR.sup.cR.sup.c, (C5 C10) aryl optionally substituted with one or more of the same or different R.sup.8 groups, phenyl optionally substituted with one or more of the same or different R.sup.8 groups, (C6 C16) arylalkyl optionally substituted with one or more of the same or different R.sup.8 groups, 5 10 membered heteroaryl optionally substituted with one or more of the same or different R.sup.8 groups and 6 16 membered heteroarylalkyl optionally substituted with one or more of the same or different R.sup.8 groups; R.sup.8 is selected from the group consisting of R.sup.a, R.sup.b, R.sup.a substituted with one or more of the same or different R.sup.a or R.sup.b, --OR.sup.a substituted with one or more of the same or different R.sup.a or R.sup.b, --B(OR.sup.a).sub.2, --B(NR.sup.cR.sup.c).sub.2, --(CH.sub.2).sub.m--R.sup.b, --(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--R.sup.b, --O--CHR.sup.aR.sup.b, --O--CR.sup.a(R.sup.b).sub.2, --O--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--CH[(CH.sub.2).sub.mR.sup.b]R.sup.b, --S--(CHR.sup.a).sub.m--R.sup.b, --C(O)NH--(CH.sub.2).sub.m--R.sup.b, --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --S--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b, --NH[(CH.sub.2).sub.mR.sup.b], --N[(CH.sub.2).sub.mR.sup.b].sub.2, --NH--C(O)--NH--(CH.sub.2).sub.m--R.sup.b, --NH--C(O)--(CH.sub.2).sub.m--CHR.sup.bR.sup.b and --NH--(CH.sub.2).sub.m--C(O)--NH--(CH.sub.2).sub.m--R.sup.b; each R.sup.35 is, independently of the others, selected from the group consisting of hydrogen and R.sup.8, or, alternatively, two R.sup.35 bonded to the same carbon atom are taken together to form an oxo (.dbd.O), NH or NR.sup.38 group and the other two R.sup.35 are each, independently of one another, selected from the group consisting of hydrogen and R.sup.8; each R.sup.36 is independently selected from the group consisting of hydrogen and (C1 C6) alkyl; each R.sup.37 is independently selected from the group consisting of hydrogen and a progroup; R.sup.38 is selected from the group consisting of (C1 C6) alkyl and (C5 C14) aryl; each R.sup.a is independently selected from the group consisting of hydrogen, (C1 C6) alkyl, (C3 C8) cycloalkyl, cyclohexyl, (C4 C11) cycloalkylalkyl, (C5 C10) aryl, phenyl, (C6 C16) arylalkyl, benzyl, 2 6 membered heteroalkyl, 3 8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4 11 membered cycloheteroalkylalkyl, 5 10 membered heteroaryl and 6 16 membered heteroarylalkyl; each R.sup.b is a suitable group independently selected from the group consisting of .dbd.O, --OR.sup.d, (C1 C3) haloalkyloxy, --OCF.sub.3, .dbd.S, --SR.sup.d, .dbd.NR.sup.d, .dbd.NOR.sup.d, --NR.sup.cR.sup.c, halogen, --CF.sub.3, --CN, --NC, --OCN, --SCN, --NO, --NO.sub.2, .dbd.N.sub.2, --N.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O)NR.sup.cR.sup.c, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --C(NH)NR.sup.cR.sup.c, --C(NR.sup.a)NR.sup.cR.sup.c, --C(NOH)R.sup.a, --C(NOH)NR.sup.cR.sup.c, --OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c, --OC(NR.sup.a)NR.sup.cR.sup.c, --[NHC(O)].sub.nR.sup.d, --[NR.sup.aC(O)].sub.nR.sup.d, --[NHC(O)].sub.nOR.sup.d, --[NR.sup.aC(O)].sub.nOR.sup.d, --[NHC(O)].sub.nNR.sup.cR.sup.c, --[NR.sup.aC(O)].sub.nNR.sup.cR.sup.c, --[NHC(NH)].sub.nNR.sup.cR.sup.c and --[NR.sup.aC(NR.sup.a)].sub.nNR.sup.cR.sup.c; each R.sup.c is independently a protecting group or R.sup.a, or, alternatively, each R.sup.c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R.sup.a or suitable R.sup.b groups; each R.sup.d is independently a protecting group or R.sup.a; each m is independently an integer from 1 to 3; each n is independently an integer from 0 to 3; and LG is a leaving group.

2. The compound of claim 1 in which LG is chloro.

3. The compound of claim 2 in which R.sup.5 is fluoro.

4. The compound of claim 3 in which R.sup.6 is hydrogen.

5. The compound of claim 1 in which Y and Z are each, independently of one another, selected from the group consisting of O and NH.

6. The compound of claim 5 in which Y and Z are each O.

7. The compound of claim 6 in which each R.sup.35 is hydrogen.

8. The compound of claim 5 in which Y is O and Z is NH.

9. The compound of claim 8 in which two R.sup.35 bonded to the same carbon atom are taken together to form an oxo group.

10. The compound of claim 9 in which the other two R.sup.35 are each hydrogen, methyl or fluoro.

11. The compound of claim 1 which is selected from the group consisting of compounds (IIf), (IIg), (IIh), (Iii), (IIj), (IIl), (IIm) and (IIn): ##STR00067## ##STR00068##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.